|
|
|
| Effects of Tiotropium Bromide Combined with Symbicort Turbuhaler on Lung Function, Exercise Tolerance and Adverse Reactions in Patients with Chronic Obstructive Pulmonary Disease |
| LIU Bin, RAN Xiangui, XING Qingfeng, et al |
| Fuyang People's Hospital, Anhui Fuyang 236000, China |
|
|
|
|
Abstract Objective: To explore the effects of tiotropium bromide combined with budesonide formoterol powder inhalant (trade name: symbicort turbuhaler) on lung function, exercise tolerance and adverse reactions in patients with chronic obstructive pulmonary disease (COPD). Methods: A total of 118 patients with acute exacerbation of COPD were selected and randomly grouped (observation group, n=59; control group, n=59). All patients were given routine symptomatic treatment, and control group was given tiotropium inhalation treatment, and observation group was given symbicort turbuhaler on the basis of above treatment. The lung function indexes, exercise tolerance, arterial gas blood analysis indexes and serum biochemical indexes were observed in the two groups before treatment and after 14 d of treatment, and the medicinal safety was evaluated in the two groups. Results: After 14 d of treatment, the lung function indexes of mean pulmonary artery pressure (MPAP), pulmonary artery systolic pressure (PASP) and pulmonary artery diastolic pressure (PADP) were significantly decreased in the the two groups (P<0.05), and the 6min walking distance (6MWD) score was improved (P<0.05), and the arterial gas blood analysis index of arterial partial pressure of oxygen (PaO2) was significantly increased (P<0.05) while the arterial partial pressure of carbon dioxide (PaCO2) was significantly decreased (P<0.05), and the levels of serum tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9) and advanced glycation end products (AGEs) were significantly decreased in the two groups (P<0.05) while the level of soluble receptor for advanced glycation end-product (sRAGE) was significantly increased (P<0.05), and the changes of the above indicators in observation group were significantly greater than those in control group (P<0.05). The total incidence rates of adverse reactions in observation group and control group were 10.17% and 6.78% respectively (P>0.05). Conclusions: Tiotropium bromide combined with symbicort turbuhaler can treat patients with acute exacerbation of COPD, and it can significantly improve lung function, enhance exercise tolerance, and reduce lung inflammatory response, and it has good clinical medicinal safety, thus it is worthy of promotion.
|
|
|
|
|
|
[1] 张志强,苏向红,等.慢性阻塞性肺疾病与病毒感染关系的研究[J].国际病毒学杂志,2016,23(2):112~113.
[2] 黄晓芬,李金田,张毅,等.毒蕈碱样胆碱能受体在慢性阻塞性肺疾病防治中的研究进展[J].中国呼吸与危重监护杂志,2016,15(1):95~98.
[3] 郭洁,武蕾,梁亚飞,等.小青龙汤加味联合信必可都保治疗对支气管哮喘患者炎症因子变化影响分析[J].中华中医药学刊,2018,36(1):207~210.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8~17.
[5] 许迎辉,李响,韩玉英.噻托溴铵联合沙美特罗丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病患者肺功能的影响[J].中国医药导报,2016,13(3)146~149.
[6] 董广锋,刘瑞娟,郭兴华.噻托溴铵抑制慢性阻塞性肺疾病气道重塑及炎症反应机制的研究进展[J].山东医药,2014,54(42):106~107.
[7] 张艳,李玲.信必可都保联合噻托溴铵对AECOPD患者PCT、TIMP-1、MMP-9、IFN-γ、动脉血气及肺功能水平的影响[J].海南医学院学报,2017,23(20):2761~2764.
[8] 李铁英.糖皮质激素对重度慢性阻塞性肺疾病急性加重期患者血清基质金属蛋白酶9和基质金属蛋白酶组织抑制因子1水平的影响研究[J].实用心脑肺血管病杂志,2016,24(2):28~31.
[9] 余霓雯,王玉婷.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF-β、MMP-9、TIMP-1水平的影响[J].东南国防医药,2017,19(2):183~186. |
|
|
|
2019, Vol. 25 
